Diruthenium(II-III)-ibuprofen-loaded chitosan-based microparticles and nanoparticles systems: encapsulation, characterisation, anticancer activity of the nanoformulations against U87MG human glioma cells

Autor(es)

Rehman, Hanif-Ur- ; Fornaciari, Barbara ; Alves, Samara R. ; Colquhoun, Alison ; Silva, Denise de Oliveira

• Tipo de documento: Artigo Científico
• Fonte: Journal of Microencapsulation; v. 40, n. 7, p. 17-pg., 2023-09-25.

Resumo

The aim of this work was to investigate novel formulations containing diruthenium(II-III)-ibuprofen (RuIbp) metallodrug encapsulated into the chitosan (CT) biopolymer. Microparticles (RuIbp/CT MPs, & SIM; 1 & mu;m) were prepared by spray-drying, and RuIbp/CT-crosslinked nanoparticles (NPs) by ionic gelation (RuIbp/CT-TPP, TPP = tripolyphosphate (1), RuIbp/CT-TPP-PEG, PEG = poly(ethyleneglycol (2)) or pre-gel/polyelectrolyte complex method (RuIbp/CT-ALG, ALG = alginate (3)). Ru analysis was conducted by energy dispersive x-ray fluorescence or inductively coupled plasma atomic emission spectroscopy, and physicochemical characterisation by powder x-ray diffraction, electronic absorption and FTIR spectroscopies, electrospray ionisation mass spectrometry, thermal analysis, scanning electron, transition electron and atomic force microscopies, and dynamic light scattering. The RuIbp-loaded nanosystems exhibited encapsulation efficiency & SIM; 20-37%, drug loading & SIM; 10-20% (w/w), hydrodynamic diameter (nm): 103.2 & PLUSMN; 7.9 (1), 91.7 & PLUSMN; 12.6 (2), 270.2 & PLUSMN; 58.4 (3), zeta potential (mV): +(47.7 & PLUSMN; 2.8) (1), +(49.2 & PLUSMN; 3.6) (2), -(28.2 & PLUSMN; 2.0) (3). Nanoformulation (1) showed the highest cytotoxicity with increased efficacy in relation to the RuIbp free metallodrug against U87MG human glioma cells. (AU)

• Processo FAPESP: 14/23047-5 - Metalofármacos anticancerígenos de rutênio com ligantes bioativos: síntese, interação com biomoléculas e preparação de sistemas biocompatíveis nanoparticulados para carregamento e liberação
• Beneficiário: Denise de Oliveira Silva
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 14/23481-7 - Estudo de nanopartículas baseadas em lipídios como carregadores de metalofármacos de rutênio com atividade anticâncer
• Beneficiário: Samara Rodrigues Alves
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto